CoChat

APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Oral squamous cell carcinoma is a prominent cancer worldwide, particularly in Taiwan. By integrating omics analyses in 50 matched samples, we uncover in Taiwanese patients a predominant mutation signature associated with cytidine deaminase APOBEC, which correlates with the upregulation of APOBEC3A expression in the APOBEC3 gene cluster at 22q13. APOBEC3A expression is significantly higher in tumors carrying APOBEC3B-deletion allele(s). High-level APOBEC3A expression is associated with better overall survival, especially among patients carrying APOBEC3B-deletion alleles, as examined in a second cohort (n = 188; p = 0.004). The frequency of APOBEC3B-deletion alleles is ~50% in 143 genotyped oral squamous cell carcinoma -Taiwan samples (27 A3B−/−:89 A3B+/−:27 A3B+/+), compared to the 5.8% found in 314 OSCC-TCGA samples. We thus report a frequent APOBEC mutational profile, which relates to a APOBEC3B-deletion germline polymorphism in Taiwanese oral squamous cell carcinoma that impacts expression of APOBEC3A, and is shown to be of clinical prognostic relevance. Our finding might be recapitulated by genomic studies in other cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-00493-9

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 An integrated deep-sequencing approach identifies novel variant features underlying OSCC of a unique demographic origin. Summary data for the 50 OSCC-Taiwan cases. The four blocks correspond to the different types of data attributes. They represent, from top to bottom: a Mutation analyses in a series of 50 OSCC samples. The y-axis shows the number of mutation events and the omics data (DNA exome sequencing, RNA RNA-Seq, CCP comprehensive cancer panel), whereas the x-axis indicates the samples of the individual patients. b Heatmap representation of individual genes exhibiting somatic mutations in the 50 OSCC samples. The q-values (false discovery rates) represent the significance of each mutated gene, as determined using MutSigCV. c Heatmap representation of the copy number variations, compared with those from TCGA and India. SNVs were identified with Mutect, which applies a Bayesian classifier to detect mutations with allelic fractions of 0.1 or less ( < 10%). For the number of mutation events, the mutation types are broken down by the indicated sequence features. For the mutation b and copy number analyses c, the tables on the right show the percentages of patients with the respective somatic sequence variation or amplification/deletion, as found in the OSCC-Taiwan (TW), OSCC-TCGA (TCGA), and OSCC-India (India) cohorts. NA data not available. d The risk exposure and A3B deletion genotypes. OSCC patients with the habits of alcohol, betel nut or cigarette are individually marked. For 3 APOBEC3B genotypes, A3B −/−, A3B +/−, and A3B +/+ are shown with full, half and empty squares, respectively
Fig. 1 An integrated deep-sequencing approach identifies novel variant features underlying OSCC of a unique demographic origin. Summary data for the 50 OSCC-Taiwan cases. The four blocks correspond to the different types of data attributes. They represent, from top to bottom: a Mutation analyses in a series of 50 OSCC samples. The y-axis shows the number of mutation events and the omics data (DNA exome sequencing, RNA RNA-Seq, CCP comprehensive cancer panel), whereas the x-axis indicates the samples of the individual patients. b Heatmap representation of individual genes exhibiting somatic mutations in the 50 OSCC samples. The q-values (false discovery rates) represent the significance of each mutated gene, as determined using MutSigCV. c Heatmap representation of the copy number variations, compared with those from TCGA and India. SNVs were identified with Mutect, which applies a Bayesian classifier to detect mutations with allelic fractions of 0.1 or less ( < 10%). For the number of mutation events, the mutation types are broken down by the indicated sequence features. For the mutation b and copy number analyses c, the tables on the right show the percentages of patients with the respective somatic sequence variation or amplification/deletion, as found in the OSCC-Taiwan (TW), OSCC-TCGA (TCGA), and OSCC-India (India) cohorts. NA data not available. d The risk exposure and A3B deletion genotypes. OSCC patients with the habits of alcohol, betel nut or cigarette are individually marked. For 3 APOBEC3B genotypes, A3B −/−, A3B +/−, and A3B +/+ are shown with full, half and empty squares, respectivelyCC BY · PubMed Central
Fig. 2 Mutational signature analysis of OSCC-Taiwan. a Three distinct mutational signatures were identified by our OSCC whole-exome sequencing. The spectra of base changes representing APOBEC (signatures 2/13), age (signature 1), and smoking (signature 4/5) are shown. The x-axis indicates the 96 combinations of trinucleotide motifs, while the y-axis represents the relative coefficient of the detected signature. b Heatmap of cosine-similarity results for the mutation spectrums of OSCC-Taiwan, coded by color. The cosine-similarity score, which ranges from 0 to 1, represents the extent of similarity to a particular signature. Among the 27 mutational signatures, the APOBEC, age, and smoking signatures are the most significant mutational signatures detected in OSCC samples (dark red). c The three overrepresented mutation signatures described in a were compared among datasets representing OSCC from Taiwan, India, and TCGA, as well as other TCGA tumor types carrying APOBEC-associated signatures. OSCC-TCGA is a subset of the HNSC (head and neck squamous cell carcinoma) data archived in TCGA. CESC, BLCA, BRCA, ESCA, LUSC, and LUAD correspond to cervical squamous cell carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, esophageal carcinoma, lung squamous cell carcinoma, and lung adenocarcinoma, respectively
Fig. 2 Mutational signature analysis of OSCC-Taiwan. a Three distinct mutational signatures were identified by our OSCC whole-exome sequencing. The spectra of base changes representing APOBEC (signatures 2/13), age (signature 1), and smoking (signature 4/5) are shown. The x-axis indicates the 96 combinations of trinucleotide motifs, while the y-axis represents the relative coefficient of the detected signature. b Heatmap of cosine-similarity results for the mutation spectrums of OSCC-Taiwan, coded by color. The cosine-similarity score, which ranges from 0 to 1, represents the extent of similarity to a particular signature. Among the 27 mutational signatures, the APOBEC, age, and smoking signatures are the most significant mutational signatures detected in OSCC samples (dark red). c The three overrepresented mutation signatures described in a were compared among datasets representing OSCC from Taiwan, India, and TCGA, as well as other TCGA tumor types carrying APOBEC-associated signatures. OSCC-TCGA is a subset of the HNSC (head and neck squamous cell carcinoma) data archived in TCGA. CESC, BLCA, BRCA, ESCA, LUSC, and LUAD correspond to cervical squamous cell carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, esophageal carcinoma, lung squamous cell carcinoma, and lung adenocarcinoma, respectivelyCC BY · PubMed Central
Fig. 3 APOBEC3 gene expression is altered in OSCC. a The mRNA expression levels of all seven APOBEC3 genes in our paired OSCC samples were determined by RNA-Seq. The y-axis shows the TPM (transcripts per million) of each gene in paired tissue samples. N, adjacent normal tissue; T, tumor tissues. The expression profiles illustrate the tumor-specific up-regulations of A3A, A3B (p < 0.0001, Mann–Whitney U-test), and A3G (p = 0.02, Mann–Whitney U-test). In tumors, A3A was expressed at a higher level than A3B (p < 0.001). b A3A-specific peptides were identified in tissue proteomes using iTRAQ-mass spectrometry. The y axis represents the protein level relative to a common reference. A3A-specific peptides were significantly higher (~3 fold) in tumor tissues compared with corresponding normal tissues (p < 0.001, Mann-Whitney U-test). Of the 38 N/T paired tissues analyzed, we detected A3A peptides in 35 normal tissue samples and 36 tumor tissue samples. c Expression levels of A3A and A3B in different TCGA cancer types. Only cancers reported to have APOBEC-mutation signatures were included in this plot; they are ordered according to the A3A expression levels in their tumors. The y-axis shows the TPM of our RNA-Seq data for the A3A and A3B genes. The HNSC samples were further grouped into OSCC and ‘others’ (HNSC-non-OSCC). UCEC, DLBC, SKCM, STAD, PAAD, THCA, KIRP, CESC, BLCA, BRCA, ESCA, LUSC, and LUAD correspond to uterine corpus endometrial carcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, skin cutaneous melanoma, stomach adenocarcinoma, pancreatic adenocarcinoma, thyroid carcinoma, kidney renal papillary cell carcinoma, cervical squamous cell carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, esophageal carcinoma, lung squamous cell carcinoma and lung adenocarcinoma, respectively. Box plots show the distribution of expression of indicated APOBEC genes. Boxes extend from the third (Q3) to the first (Q1) quartile, with the line at the median; whiskers extend to 2.5 and 97.5 percentiles
Fig. 3 APOBEC3 gene expression is altered in OSCC. a The mRNA expression levels of all seven APOBEC3 genes in our paired OSCC samples were determined by RNA-Seq. The y-axis shows the TPM (transcripts per million) of each gene in paired tissue samples. N, adjacent normal tissue; T, tumor tissues. The expression profiles illustrate the tumor-specific up-regulations of A3A, A3B (p < 0.0001, Mann–Whitney U-test), and A3G (p = 0.02, Mann–Whitney U-test). In tumors, A3A was expressed at a higher level than A3B (p < 0.001). b A3A-specific peptides were identified in tissue proteomes using iTRAQ-mass spectrometry. The y axis represents the protein level relative to a common reference. A3A-specific peptides were significantly higher (~3 fold) in tumor tissues compared with corresponding normal tissues (p < 0.001, Mann-Whitney U-test). Of the 38 N/T paired tissues analyzed, we detected A3A peptides in 35 normal tissue samples and 36 tumor tissue samples. c Expression levels of A3A and A3B in different TCGA cancer types. Only cancers reported to have APOBEC-mutation signatures were included in this plot; they are ordered according to the A3A expression levels in their tumors. The y-axis shows the TPM of our RNA-Seq data for the A3A and A3B genes. The HNSC samples were further grouped into OSCC and ‘others’ (HNSC-non-OSCC). UCEC, DLBC, SKCM, STAD, PAAD, THCA, KIRP, CESC, BLCA, BRCA, ESCA, LUSC, and LUAD correspond to uterine corpus endometrial carcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, skin cutaneous melanoma, stomach adenocarcinoma, pancreatic adenocarcinoma, thyroid carcinoma, kidney renal papillary cell carcinoma, cervical squamous cell carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, esophageal carcinoma, lung squamous cell carcinoma and lung adenocarcinoma, respectively. Box plots show the distribution of expression of indicated APOBEC genes. Boxes extend from the third (Q3) to the first (Q1) quartile, with the line at the median; whiskers extend to 2.5 and 97.5 percentilesCC BY · PubMed Central
Fig. 4 The deletion polymorphism of the A3A-A3B genomic locus and upregulation of A3A and A3B in OSCC-Taiwan. a Schematic depiction of the gene structures and genomic organizations of the deletion polymorphism (top) and non-deleted (bottom) versions of the APOBEC3A-APOBEC3B genomic locus. The deletion variant (APOBEC3A_B genotype) arises from a 29.5-kb genomic deletion spanning from the 3’UTR of A3A to the eighth exon of A3B. PCR-based genotyping analysis was used to distinguish non-deletion and deletion alleles according to the size of the amplified product (449 and 757 bp, respectively). A3B +/+, A3B +/−, and A3B −/− represent non-carrier individuals and those heterozygous and homozygous for the deletion allele, respectively. b Genotype-biased expressional alterations of A3A and A3B in OSCC. Based on RNA-Seq-determined TPM values (y-axis), the mRNA expression levels of A3A (left) and A3B (right) were determined in the initial cohort of 39 paired samples (N, adjacent normal tissues; T, tumor). Patients are grouped according to their APOBEC3B-deletion genotypes, with the number of patients in each group (n) indicated at the top. c Genotype-specific relative expression of A3A in tumor (T) vs. normal tissue (N) samples, as determined by RT-PCR. The y-axis represents the expression level of A3A (or A3B) relative to that of TBP (TATA binding protein gene). Individuals of the A3B −/− genotype exhibited a greater tumor-specific upregulation of A3A compared with those of the A3B +/− genotype (p = 0.0354) (*p < 0.05; **p < 0.001; ***p < 0.0001, Wilcoxon signed-rank test). Box plots show the distribution of expression of indicated APOBEC genes. Boxes extend from the third (Q3) to the first (Q1) quartile, with the line at the median; whiskers extend to 2.5 and 97.5 percentiles
Fig. 4 The deletion polymorphism of the A3A-A3B genomic locus and upregulation of A3A and A3B in OSCC-Taiwan. a Schematic depiction of the gene structures and genomic organizations of the deletion polymorphism (top) and non-deleted (bottom) versions of the APOBEC3A-APOBEC3B genomic locus. The deletion variant (APOBEC3A_B genotype) arises from a 29.5-kb genomic deletion spanning from the 3’UTR of A3A to the eighth exon of A3B. PCR-based genotyping analysis was used to distinguish non-deletion and deletion alleles according to the size of the amplified product (449 and 757 bp, respectively). A3B +/+, A3B +/−, and A3B −/− represent non-carrier individuals and those heterozygous and homozygous for the deletion allele, respectively. b Genotype-biased expressional alterations of A3A and A3B in OSCC. Based on RNA-Seq-determined TPM values (y-axis), the mRNA expression levels of A3A (left) and A3B (right) were determined in the initial cohort of 39 paired samples (N, adjacent normal tissues; T, tumor). Patients are grouped according to their APOBEC3B-deletion genotypes, with the number of patients in each group (n) indicated at the top. c Genotype-specific relative expression of A3A in tumor (T) vs. normal tissue (N) samples, as determined by RT-PCR. The y-axis represents the expression level of A3A (or A3B) relative to that of TBP (TATA binding protein gene). Individuals of the A3B −/− genotype exhibited a greater tumor-specific upregulation of A3A compared with those of the A3B +/− genotype (p = 0.0354) (*p < 0.05; **p < 0.001; ***p < 0.0001, Wilcoxon signed-rank test). Box plots show the distribution of expression of indicated APOBEC genes. Boxes extend from the third (Q3) to the first (Q1) quartile, with the line at the median; whiskers extend to 2.5 and 97.5 percentilesCC BY · PubMed Central
Fig. 5 Kaplan–Meier plot for overall survival (OS) by A3A and A3B expression and genotype in OSCC-Taiwan and OSCC-TCGA. a Kaplan–Meier plot showing that the 10-year OS rates for patient subgroups stratified by high vs. low A3A expression were 85.1% and 65.9%, respectively (p = 0.004) in the OSCC-Taiwan data set, whereas no significant difference was found in the OSCC-TCGA data set (p = 0.239). b No significant difference in OS was found for subgroups stratified according to A3B expression (right) in the OSCC-Taiwan and OSCC-TCGA datasets. c Kaplan–Meier plot for OS in subgroups stratified by A3A expression among the 143 patients in the OSCC-Taiwan data set. High A3A in patients with the A3B +/− (n = 89) and A3B −/− (n = 27) genotypes, but not the A3B +/+ (n = 27) genotype, was significantly correlated with better OS. d Kaplan–Meier plot for OS in subgroups stratified by A3A expression among the 312 patients in the OSCC-TCGA data set. No significant correlation was found in patients with the A3B +/+ (n = 278) or A3B +/− (n = 34) genotypes. The y-axis shows the probability of OS according to high and low A3A expression. The survival rate was estimated by Kaplan–Meier plotting and compared by log-rank test; all p-values are two-sided, with the significance level set at p < 0.05
Fig. 5 Kaplan–Meier plot for overall survival (OS) by A3A and A3B expression and genotype in OSCC-Taiwan and OSCC-TCGA. a Kaplan–Meier plot showing that the 10-year OS rates for patient subgroups stratified by high vs. low A3A expression were 85.1% and 65.9%, respectively (p = 0.004) in the OSCC-Taiwan data set, whereas no significant difference was found in the OSCC-TCGA data set (p = 0.239). b No significant difference in OS was found for subgroups stratified according to A3B expression (right) in the OSCC-Taiwan and OSCC-TCGA datasets. c Kaplan–Meier plot for OS in subgroups stratified by A3A expression among the 143 patients in the OSCC-Taiwan data set. High A3A in patients with the A3B +/− (n = 89) and A3B −/− (n = 27) genotypes, but not the A3B +/+ (n = 27) genotype, was significantly correlated with better OS. d Kaplan–Meier plot for OS in subgroups stratified by A3A expression among the 312 patients in the OSCC-TCGA data set. No significant correlation was found in patients with the A3B +/+ (n = 278) or A3B +/− (n = 34) genotypes. The y-axis shows the probability of OS according to high and low A3A expression. The survival rate was estimated by Kaplan–Meier plotting and compared by log-rank test; all p-values are two-sided, with the significance level set at p < 0.05CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 115

Metadata

Authors
Chen, T.-W., Lee, C.-C., Liu, H., Wu, C.-S., Pickering, C. R., Huang, P.-J., Wang, J., Chang, I. Y.-F., Yeh, Y.-M., Chen, C.-D., Li, H.-P., Luo, J.-D., Tan, B. C.-M., Chan, T. E. H., Hsueh, C., Chu, L. J., Chen, Y.-T., Zhang, B., Yang, C.-Y., Wu, C.-C., Hsu, C.-W., See, L.-C., Tang, P., Yu, J.-S., Liao, W.-C., Chiang, W.-F., Rodriguez, H., Myers, J. N., Chang, K.-P., & Chang, Y.-S.
Affiliations
  • Chang Gung University (TW)
  • The University of Texas MD Anderson Cancer Center (US)
  • Baylor College of Medicine (US)
  • Chi Mei Medical Center (TW)
  • National Institutes of Health (US)
  • Chang Gung Memorial Hospital (TW)
Corresponding author
  • Chang, Kai-Ping
  • Chang, Yu-Sun
Venue
Nature Communications
Published
2017-09-06
Volume
8
Issue
1
Pages
465-465
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2752473528
Cited by
115
References
59
Citations by year
2026: 5 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 24 · 2021: 18 · 2020: 16 · 2019: 15 · 2018: 16
FWCI
4.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Wellcome Trust
  • National Applied Research Laboratories
  • Chang Gung Medical Foundation
  • Ministry of Science and Technology, Taiwan (MOST104-2320-B182-033-MY3, MOST105-2632-B182-001, MOST103-2632-B182-001, MOST104-2325-B492-001, MOST104-2632-B182-001)
  • National Research Program for Biopharmaceuticals
  • National Human Genome Research Institute
  • National Cancer Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Health Sciences › Dentistry › General Dentistry › Oral Health Pathology and Treatment
Keywords
APOBEC3A, APOBEC3B, oral squamous cell carcinoma, APOBEC mutational signature, germline polymorphisms, prognostic factors, overall survival, cytidine deaminase, Taiwanese patients, mutational profiling
MeSH terms
Adult, Carcinoma, Squamous Cell, Cytidine Deaminase, Female, Humans, Male, Middle Aged, Mouth Neoplasms, Polymorphism, Genetic, Proteins, Taiwan, Biomarkers, Tumor, Cohort Studies, Gene Expression Regulation, Neoplastic, Sequence Deletion, Germ-Line Mutation, Asian People, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. https://app.cochat.ai/papers/10.1038/s41467-017-00493-9
The paper
Chen, T.-W., Lee, C.-C., Liu, H., Wu, C.-S., Pickering, C. R., Huang, P.-J., Wang, J., Chang, I. Y.-F., Yeh, Y.-M., Chen, C.-D., Li, H.-P., Luo, J.-D., Tan, B. C.-M., Chan, T. E. H., Hsueh, C., Chu, L. J., Chen, Y.-T., Zhang, B., Yang, C.-Y., . . . Chang, Y.-S. (2017). APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nature Communications. https://doi.org/10.1038/s41467-017-00493-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.